Mian AA, Zafar U, Ottmann O, Ruthardt M and Lalani E-N (2019). Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukaemia (ALL) Leads to Non-Mutational Resistance. Blood (2019) 134 (Supplement_1): 2570. doi.org/10.1182/blood-2019-130898.
Zafar U, Yusuf M, Chakraborty R, Lalani E-N and Mian AA (2019). The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukaemia. Blood (2019) 134 (Supplement_1): 5196. doi.org/10.1182/blood-2019-131694.
Ali S, Khan FA, Mian AA, and Afzal MS (2014). Seroprevalence of Cytomegalovirus, Herpes Simplex Virus and Rubella Virus Among Pregnant Women in the KPK Province of Pakistan. J Infect Dev Ctries, 8(3), 389-390. doi:10.3855/jidc.3854.
Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, and Ruthardt M (2008). Targeting of the N-terminal Coiled-Coil Oligomerization Interface by a Helix-2 Peptide Inhibits Unmutated and Imatinib-resistant BCR/ABL. Int J Cancer, 122(12), 2744-2752. doi:10.1002/ijc.23467.
Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, and Mian AA (2016). BCR: A New Target in Resistance Mediated by BCR/ABL-315I? Genes Cancer, 7(1-2), 36-46.
doi:10.18632/genesandcancer.93.
Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian AA, Metodieva A, . . . Mahajna J (2012). Overcoming Bcr-Abl T315I Mutation by Combination of GNF-2 and ATP Competitors in an ABL-Independent Mechanism. BMC Cancer, 12, 563. doi:10.1186/1471-2407-12-563.
Legut M, Dolton G, Mian AA, Ottmann OG and Sewell AK (2018). CRISPR-mediated TCR Replacement Generates Superior Anticancer Transgenic T cells. Blood, 131(3), 311-322.
doi:10.1182/blood-2017-05-787598.
Mian AA, Haberbosch I, Ottmann GO and Ruthardt M (2104). Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL.
Blood, 124(21), 4523.
Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, . . . Ruthardt M (2012). Allosteric Inhibition Enhances the Efficacy of ABL Kinase Inhibitors to Target Unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer, 12, 411. doi:10.1186/1471-2407-12-411.
Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J and Ruthardt M (2012). p185(BCR/ABL) Has a Lower Sensitivity Than p210(BCR/ABL) to the Allosteric Inhibitor GNF-2 in Philadelphia Chromosome-Positive Acute Lymphatic Leukaemia. Haematologica, 97(2), 251-257. doi:10.3324/haematol.2011.047191.
Mian AA, Metodieva A, Najajreh Y, Serve H, Ottmann OG, Mahajna J and Ruthardt M (2010). The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL. Blood, 116(21), 598.
Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M (2009). Oligomerization Inhibition, Combined with Allosteric Inhibition, Abrogates the Transformation Potential of T315I-Positive BCR/ABL. Leukaemia, 23(12), 2242-2247. doi:10.1038/leu.2009.194.
Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, . . . Ruthardt M (2015). PF-114, A Potent and Selective Inhibitor of Native and Mutated BCR/ABL Is Active Against Philadelphia Chromosome Positive (Ph+) Leukaemias Harboring the T315I Mutation. Leukaemia, 29(5), 1104-1114. doi:10.1038/leu.2014.326.
Mian AA, Rafiei A, Metodieva A, Haberbosch I, Zeifman A, Titov I, . . . Ruthardt M (2013). PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets the T315I and Suppress Models of Advanced Ph+ ALL. Blood, 122(21), 3907.
Mian AA, Schull M, Oancea C, Najajreh Y, Mahajna J, Goldblum A, . . . Ruthardt M (2011). Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia Chromosome Positive Leukaemic Cells. The Open Hematology Journal, 5, 21-27. doi:10.2174/1874276901105010021.
Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, . . . Ruthardt M (2009). The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL- Kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-of-Function Mutants of BCR/ABL. Leukaemia, 23(9), 1614-1621. doi:10.1038/leu.2009.69.
Oancea C, Ruster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA . . . Ruthardt M (2014). STAT Activation Status Differentiates Leukemogenic From Non-leukemogenic Stem Cells in AML and is Suppressed by Arsenic in t(6;9)-Positive AML. Genes Cancer, 5(11-12), 378-392. doi:10.18632/genesandcancer.39.
Rafiei A, Mian AA, Doring C, Metodieva A, Oancea C, Thalheimer FB, . . . Ruthardt M (2015). The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukaemia. PLoS Genet, 11(4), e1005144. doi:10.1371/journal.pgen.1005144.
